NCT06735742View on ClinicalTrials.gov

A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

April 12, 2025

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions
Breast Cancer
Trial Locations (1)

Unknown

Pfizer Japan, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY